The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...
J&J wins FDA nod for Icotyde, a once-daily oral psoriasis pill, boosting its new drugs portfolio and challenging injectable treatments in a key market.
AbbVie (ABBV) stock dips as BNP warns J&J’s (JNJ) newly FDA-approved plaque psoriasis pill, Icotyde, may challenge its blockbuster drug, Skyrizi. Read more here.
Everyday Health on MSN
FDA approves first-of-its-kind daily pill for moderate to severe psoriasis
The first-of-its-kind oral pill could replace injectable medications for some patients with psoriasis, dermatologists say.
While Johnson & Johnson retains the top revenue rank across the major pharma companies, Eli Lilly last year established ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results